52 results about "Aldosterone" patented technology

The present invention belongs to the technical field of chemical pharmaceuticals. Provided in the present invention are an aldosterone synthetase inhibitor, and a preparation method therefor and the use thereof.

The invention discloses a pyranopyridine compound as well as a preparation method, a pharmaceutical composition and application thereof. The invention provides a compound as shown in a formula (I), a pharmaceutically acceptable salt or a stereoisomer thereof, and the compound has a relatively strong inhibition effect on aldosterone synthetase, almost has no influence on cortisol synthetase, has high selectivity and relatively high safety, and can be used for preventing and / or treating various diseases related to aldosterone. # imgabs0 #

The invention relates to the technical field of medical detection, in particular to a method for detecting aldosterone, cortisol, deoxycorticosterone and cortisone in plasma through LC-MS / MS. The method comprises the following steps: (a) mixing a plasma sample with an internal standard solution to obtain a mixed solution; (b) adding the mixed solution into the magnetic bead suspension, sequentially carrying out adsorption, weak washing, strong washing and elution, and collecting an eluent; (c) carrying out liquid nitrogen blowing and redissolving on the eluent, and then carrying out LC-MS / MS detection; wherein the surfaces of the magnetic beads are modified with steroid adsorption groups, and the target detection objects are aldosterone, cortisol, deoxycorticosterone and cortisone. The detection method is convenient and simple, the detection efficiency is higher than that of a traditional method, and a feasible solution is provided for promoting popularization and application of the LC-MS / MS technology in clinical practice.

The invention relates to the technical field of medical detection, in particular to an endocrine hypertension screening method based on immunological analysis, which comprises the following steps: collecting a random urine sample, removing interferents by using a composite nano adsorbent, and synchronously detecting hormones such as aldosterone, methoxyadrenaline and cortisol and metabolites thereof by using a high-throughput immunity analyzer; integrating detection data based on a dynamic threshold algorithm to generate a screening report, carrying out weighted scoring on positive samples in combination with clinical features, screening high-risk candidate samples, carrying out 24-hour urine retest on the high-risk samples, and if a retest result is still positive, carrying out referral treatment to a specialized department for disease cause definite diagnosis; according to the method, the technical problems of complex sample treatment, low multi-step efficiency and high false positive rate in the prior art are solved, efficient and accurate screening of endocrine hypertension is realized, and reliable support is provided for early diagnosis and targeted treatment.

Provided herein are methods of reducing the amount of AGT RNA and / or AGT protein in a subject having or at risk for heart failure, such as heart failure with reduced ejection fraction (HFrEF), heart failure with mid-range ejection fraction (HFmrEF), or heart failure with preserved ejection fraction (HFpEF), and, in particular instances, a subject who is, or is at risk of being, intolerant to treatment with a renin-angiotensin-aldosterone system (RAAS) inhibitor. Also provided herein are methods for treating heart failure (such as HFrEF, HFmrEF or HFpEF). Methods provided herein include administering to a subject an oligomeric agent containing a modified oligonucleotide containing a nucleobase sequence complementary to a sequence in an AGT nucleic acid, such as ION904. Further provided herein are pharmaceutical compositions containing ION904.

The present invention concerns selective renal denervation treatment of drug resistant hypertensive patients by correlating the patients' genetic panel by categorization and hierarchy according to patients' genetic variants within the functional genes for heart activity, for the renin-angiotensin aldosterone system, and for renal activity.

The invention provides an aldosterone antigen binding molecule and application thereof, and relates to the technical field of biology. The aldosterone antigen binding molecule is selected from a first antigen binding molecule containing CDR sequences as shown in SEQ ID NO.1 and SEQ ID NO.2 or a second antigen binding molecule containing CDR sequences as shown in SEQ ID NO.3 and SEQ ID NO.4. The aldosterone antigen binding molecule can bind an aldosterone antigen, and can be used for a method or a product for detecting aldosterone based on an immunological principle; the first antigen binding molecule and the second antigen binding molecule can also form an immune complex with a double-antibody sandwich structure with aldosterone, so that aldosterone is detected by a double-antibody sandwich principle.

The invention relates to the technical field of traditional Chinese medicines, in particular to application of a traditional Chinese medicine composition in preparation of medicines for preventing and treating hypertension. The traditional Chinese medicine composition comprises sedum sarmentosum, seaweed, oyster, hawthorn, herba siegesbeckiae, schisandra chinensis and polygonum cuspidatum. The composition is found to be capable of remarkably inhibiting a renin-angiotensin-aldosterone system, regulating vascular active factors, relaxing vascular smooth muscles, protecting vascular endothelial functions, reducing heart left ventricular hypertrophy and effectively reducing systolic pressure and diastolic pressure. The traditional Chinese medicine composition is an existing Chinese patent medicine, medication is safe, and the preparation method is simple, rapid, efficient and easy to operate. The prepared mixture, tablet, capsule, pellet and the like are convenient to carry and take.

Disclosed in the present invention are a pyrano-pyridine compound, a preparation method therefor, a pharmaceutical composition thereof and the use thereof. Provided in the present invention are a compound as shown in formula (I), a pharmaceutically acceptable salt thereof or a stereoisomer thereof. These compounds have a stronger inhibitory effect on aldosterone synthetase, but have almost no influence on cortisol synthetase, have high selectivity and higher safety, and can be used for preventing and / or treating various diseases related to aldosterone.

The invention discloses a metabolic marker aldosterone for screening heat stress Hu sheep as well as a screening method and application thereof, and belongs to the technical field of livestock serum markers. The metabolic marker for screening the heat stress Hu sheep is aldosterone; the screening method comprises the following steps: (1) taking blood of known heat-sensitive Hu sheep or heat-resistant Hu sheep as a standard test sample, taking blood of Hu sheep to be detected as a detection sample, and centrifuging to obtain a serum sample; (2) detecting the aldosterone concentration in the serum sample; and (3) calculating the aldosterone concentration average value of the standard test sample, taking the calculated aldosterone concentration critical value as a reference level, if the aldosterone concentration of the detection sample is higher than the reference level, determining that the detection sample is a heat-resistant Hu sheep, and if the aldosterone concentration of the detection sample is lower than the reference level, determining that the detection sample is a heat-sensitive Hu sheep. The aldosterone is used as the marker for detection, has the characteristics of high accuracy and high sensitivity, and can be directly used as an evaluation index for distinguishing the heat-sensitive Hu sheep from the heat-resistant Hu sheep.

The present invention relates to novel compounds and pharmaceutical compositions thereof, and to methods for promoting healthy skin aging, treating skin disorders, treating cardiovascular disorders, treating renal disorders, treating angiogenesis disorders, such as cancer, treating tissue damage, such as non-cardiac tissue damage, treating progressive myocardial infarction, and treating various other disorders, such as complications resulting from diabetes with the compounds and compositions of the invention. Other disorders may include, but are not limited to, atherosclerosis, coronary artery disease, diabetic nephropathy, diabetic neuropathy, diabetic retinopathy, skin infections, peripheral vascular disease, stroke, and the like.

The present disclosure relates to the use of angiotensin-converting enzyme and / or angiotensin-converting enzyme 2 as a fecal biomarker for the diagnosis of a disease or disorder related to the renin-angiotensin-aldosterone system, and also to the use of angiotensin-converting enzyme and angiotensin-converting enzyme 2 isoforms as fecal biomarkers for the detection of dysbiosis.

This application belongs to the field of immunoassay technology, and discloses an aldosterone sandwich antibody mAb5 or its antigen-binding fragment, its preparation method, and its applications. The aldosterone sandwich antibody mAb5 or its antigen-binding fragment includes a light chain variable region (VL) and a heavy chain variable region (VH). The light chain variable region (VL) includes complementarity-determining regions (LCDR1, LCDR2, and LCDR3), whose amino acid sequences are shown in SEQ ID NO. 1-3, respectively. The heavy chain variable region (VH) includes complementarity-determining regions (HCDR1, HCDR2, and HCDR3), whose amino acid sequences are shown in SEQ ID NO. 4-6, respectively. Using the aldosterone sandwich antibody mAb5 of this application to detect aldosterone standard antigens, the detection sensitivity is less than 7 pg / mL. Magnetochemiluminescence immunoassay of clinical samples shows good correlation with clinical results within the sample range of 0-1000 pg / mL, which is of great significance in the diagnosis and treatment of essential hypertension and other aldosterone-related diseases.

The application discloses a plant extraction compound for reducing blood pressure, a preparation method and application thereof. The compound is composed of high-purity silybin extract and a specific fusion polypeptide through molecular self-assembly. The sequence of the fusion polypeptide is shown in sequence SEQ ID NO:1, which innovatively integrates cell membrane penetration function, angiotensin II receptor 1 antagonism function and hydrophobic drug binding function. The core of the application is that through polypeptide-mediated active targeting, silybin is accurately delivered to the diseased blood vessel area, and the double synergistic mechanism of upstream ACE inhibition and downstream receptor blocking of the renin-angiotensin-aldosterone system is realized. In-vivo pharmacodynamic experiments prove that compared with single components, the compound can produce more significant and persistent antihypertensive effect, and can effectively reverse myocardial hypertrophy and fibrosis caused by hypertension, and show excellent synergistic therapeutic effect and target organ protection ability.

The present Invention relates to a newly designed product, i.e. substance (B+C) that combines two different mechanisms of action that allow the control of aldosterone synthesis and secretion without compromising the metabolism of cortisol (corticosterone In rats) in the.tone glomerulosa of the adrenal gland. The innovative design of the described molecule enables ths individual use of substance (B+C) in the treatment of diseases such as hyper and hypo aldosteronism, Conn's syndrome and cytokine storm caused by Covid infection or as co-therapy with corticosteroids in the treatment of a whole range of immunological diseases. The innovative design of Substance (8+C) has an additional practical and economic advantage because the patient receives both components of substance (B+C) simultaneously with just one application, regardless of the medicine formulation. This not only simplifies the medicine synthesis, dosing and clinical research, but also the application of the medicine in clinical practice. For successful and selective control of aldosterone synthesis, which in nature also means selective control of blood pressure, it was necessary to combine the two substances described in order to ensure action in patients with elevated and / or towered blood pressure with one application of Substance (B+C). This feature of Substance (B+C) is important, especially in the treatment of patients with permanently impaired aldosterone synthesis, such as Conn's disease and similar autoimmune diseases, or in combmatton with corticosteroids where prolonged or repeated corticosteroid therapy is indicated. Finally, this invention is extremely important because It enables the safe treatment of a large group of patients with hypertension who also have secondary diseases of the immune system, various inflammations or viral Infections such as Covid where corticosteroid therapy is indicated, but difficult to implement in practice due to the negative effect of corticosteroids on blood pressure.

The invention relates to application of an activating agent in promotion of uranium element discharge. Specifically, the activating agent is prepared from rifampicin, erythromycin, progesterone, aldosterone, bilirubin, cholate vinblastine, doxomicin, adriamycin, paclitaxel, bosentan, ambrisentan, digoxin, verapamil, tonavir, amprenavir, indinavir, hypericum perforatum juice, curcumin, atorvastatin beclomethasone, budesonide, divaricasone carbamazepine and caffeine. And phenytoin. The use dosage of the activating agent is 10 to 60 mg / kg. According to the method, the accumulation amount of uranium in important organs such as bones and kidneys can be remarkably reduced, so that the potential toxic influence on the key organs is reduced.

Embodiments provide for methods of treatment for subjects suffering from a condition / disorder or disease for which the renin-angiotensin-aldosterone system (RAAS) plays at least some role. In one example, a method comprises administering to the subject an effective amount of one or more of an angiotensin receptor AT2R antagonist for a duration sufficient to elicit a desired response in the subject suffering from pancreatic cancer. The administering acts to reduce proliferation of tumor cells associated with the pancreatic cancer.

The application discloses a kind of medium chain inulin and its preparation method and application, belong to plant extraction technical field.The unique inulin structure and chain length disclosed in the application remodel intestinal microbiome and metabolome, especially selectively regulate key microorganisms such as coprococcus, bifidobacterium, parabacteroides, Clostridium_sensu_stricto_1 and Akkermansia, and metabolites such as nicotinamide, taurocholic acid, aldosterone, corticosterone, 2-(1H-indole-3-yl)acetic acid, 5-hydroxy-L-tryptophan, 5alpha-DHT and maltose, promote the improvement of host obesity and overall health status.The core microorganisms and metabolites identified by the technical scheme represent potential therapeutic targets for preventing or treating obesity and related metabolic symptoms.These findings support the development of inulin-based nutritional strategies to effectively manage weight by regulating specific microbiota and metabolome.

The purpose is to provide plasma biomarkers for bone infections in humans. [Solution] The plasma biomarker for bone infection consists of one or more substances selected from the group consisting of sphingosine-1-phosphate, taurocholic acid, glycololic acid, 11a,b-hydroxyprogesterone, 15(S)-HETE-2, 13-dehydrochenodeoxycholic acid, 3,21-dihydroxy-5a-pregnan-20-one-2, aldosterone, bisacrone-2, naringenin, tauro-a-muricholic acid-6, 1-deoxysphingosine, 12(S)-HETE-2, 2-arachidonoylglycerol, 3-hydroxydodecanoic acid, 3-hydroxytetradecanoic acid, 3b-hydroxy-5-cholestenoic acid, AEA(22:4)-1, AEA(22:4)-2, bilverdin, sphingosine, malic acid, and succinic acid.

The application discloses a nucleic acid aptamer and derivatives, application and kit capable of specifically combining with aldosterone, and comprises a nucleotide sequence shown in SEQ ID No. 1, or a nucleotide sequence with high homology with the nucleotide sequence shown in SEQ ID No. 1 and capable of specifically combining with aldosterone, or a nucleotide sequence derived from the nucleotide sequence shown in SEQ ID No. 1 and capable of specifically combining with aldosterone. The application provides a nucleic acid aptamer and derivatives capable of combining with aldosterone, which have high specificity, stable chemical properties, are easy to preserve and label, and also correspondingly provides a screening method and application of the nucleic acid aptamer.

The invention provides application of aldosterone in diagnosis of amyotrophic lateral sclerosis, and particularly provides application of a reagent for detecting the aldosterone level in a sample in preparation of products for in-vitro diagnosis, auxiliary diagnosis and / or illness monitoring of amyotrophic lateral sclerosis. By simply detecting the aldosterone level in a serum sample, accurate diagnosis and illness monitoring of ALS can be realized.

The invention relates to the technical field of molecular biology, and provides a marker combination for diagnosing neonatal necrotizing enterocolitis and application thereof. The marker combination comprises a CC chemokine ligand 20, a heparin binding epidermal growth factor, angiotensin and aldosterone. Four markers related to neonatal necrotizing enterocolitis are obtained through research and screening, whether neonatal necrotizing enterocolitis occurs or not and the severity of neonatal necrotizing enterocolitis can be effectively judged based on the markers, and the markers have high sensitivity and specificity and can be used for detecting neonatal necrotizing enterocolitis. The kit can help clinical diagnosis and prognosis of neonatal necrotizing enterocolitis.

Provided herein is a pharmaceutical composition for treating resistant hypertension, which includes amlodipine, chlorthalidone, and amiloride. This disclosure also provides an application of the pharmaceutical composition in the treatment of low renin / low aldosterone resistant hypertension and targeting organ damage in the subject suffering from resistant hypertension.

The present invention provides a combination comprising (a) a sulfonylurea; and (b) at least one of the following components: (i) an insulin modulator and (ii) an aldosterone antagonist, for example in combinations comprising (a) glibenclamide or a structural or functional analog thereof; and (b) at least one of the following components: (i) exenatide or a structural or functional analogue thereof or a pharmaceutically acceptable salt thereof; and (ii) potassium canlylate or a structural or functional analogue thereof. The combination is suitable for use in the treatment of stroke and other neurodegenerative conditions, as well as in the treatment and / or prevention of ischemia and / or reperfusion injury of various important organs, including the brain and heart. Other aspects of the invention relate to pharmaceutical products and pharmaceutical compositions comprising the combination according to the invention, as well as methods of treatment using the same.

The invention relates to an application of urolithin A in preparation of a product for improving an endogenous estrogen level. The molecular formula of the urolithin A is C13H8O4, and the structural formula of the urolithin A is shown as a formula (I). The improvement of the endogenous estrogen level comprises the following steps: selectively regulating and controlling synthesis pathways of adrenal hormone and ovarian estrogen, and synergistically improving the in-vivo estrogen level. Besides, the urolithin A has good hormone regulation selectivity, can effectively inhibit cortisol secretion, and has no obvious influence on aldosterone level, so that blood pressure regulation and body fluid homeostasis are prevented from being interfered. The action characteristics lay a foundation for the application of the urolithin A in improvement of female climacteric hormone disorder and related health support directions, and the urolithin A has a wide prospect as an endogenous hormone regulation strategy. (I)

The invention discloses an anti-aldosterone antibody and application thereof, and relates to the field of antibodies. The anti-aldosterone antibody disclosed by the invention comprises a heavy chain complementarity determining region and a light chain complementarity determining region, provides an important raw material source for aldosterone detection, and has good affinity or activity.

The present invention belongs to the technical field of chemical pharmaceuticals. Provided in the present invention are an aldosterone synthetase inhibitor, and a preparation method therefor and the use thereof.

The invention discloses a protein pretreatment method, a renin angiotensin aldosterone system index detection method, a kit and application, and relates to the field of liquid chromatography-tandem mass spectrometry detection.The protein pretreatment method comprises the following steps that a biological sample containing renin angiotensin aldosterone system indexes is taken; mixing with an inhibitor solution, incubating, and adding a terminating agent to terminate the reaction to obtain an incubation solution; uniformly mixing the incubation solution with an internal standard solution and a protein precipitant, sequentially standing, centrifuging, and collecting supernate to obtain a sample to be detected. The protein precipitation pretreatment method provided by the invention can simplify the operation process, reduce the experiment cost, adapt to large-scale detection, efficiently remove impure proteins, weaken the matrix effect and improve the detection sensitivity and accuracy of a target object, and has a wide application prospect in the related field of RAAS system index detection.

The invention provides a deuterated 1, 2, 4-triazine compound or a pharmaceutically acceptable salt, a prodrug, a hydrate, a solvate, an enantiomer, a diastereoisomer and application of the deuterated 1, 2, 4-triazine compound or the pharmaceutically acceptable salt, prodrug, hydrate, solvate, enantiomer and diastereoisomer. The compound provided by the invention has the effect of inhibiting aldosterone synthetase, particularly can inhibit CYP11B2 with high selectivity, and also has excellent druggability, so that the compound can be used for treating diseases related to aldosterone synthetase.

The aim is to provide plasma biomarkers for bone infections in humans. [Solution] A plasma biomarker for bone infection comprising one or more substances selected from the group consisting of sphingosine-1-phosphate, taurocholic acid, glycololic acid, 11a,b hydroxyprogesterone, 15(S)-HETE-2, 13-dehydrochenodeoxycholic acid, 3,21-didihydroxy-5a-pregnane-20-one-2, aldosterone, bisacron-2, naringenin, tauro-α-mulicolic acid-6, 1-deoxysphingosine, 12(S)-HETE-2, 2-arachidonoylglycerol, 3-hydroxydodecanoic acid, 3-hydroxytetradecanoic acid, 3b-hydroxy-5-cholestic acid, AEA(22:4)-1, AEA(22:4)-2, bilbertin, sphingosine, malic acid, and succinic acid.